Form 4: Teva Director Perry Nisen Reports Share Transactions
Statement of Changes in Beneficial Ownership
Teva Pharmaceutical Industries Ltd. director Perry Nisen has reported the acquisition of 14,492 ordinary shares through the vesting of restricted share units.
Summary
- Director Perry Nisen acquired 14,492 ordinary shares of Teva Pharmaceutical Industries Ltd.
- The acquisition occurred on June 5, 2026, through the vesting of restricted share units.
- These restricted share units were originally granted on June 5, 2025.
- Following this transaction, Nisen beneficially owns 119,807 ordinary shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction related to equity compensation vesting rather than a strategic business development or financial performance indicator.
Positives
- Director Perry Nisen's beneficial ownership of Teva shares has increased.
- The transaction reflects the fulfillment of a previously granted equity award, indicating continued incentive alignment for management.
Future Outlook
No specific forward-looking statements or guidance were provided in this filing.
Industry Context
StockSavvy.ai notes that this Form 4 filing by a director of Teva Pharmaceutical Industries Ltd. is a routine disclosure of equity transactions, common within the pharmaceutical sector as companies utilize equity-based compensation to attract and retain talent.
Stakeholder Impact
- Shareholders: The transaction reflects a director's compensation and does not immediately indicate a change in the company's fundamental value, though it increases the director's stake.
- Employees: The vesting of restricted share units is a form of employee compensation, aligning management interests with shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/05/2025 | Date restricted share units were granted. |
| 06/05/2026 | Date restricted share units vested and ordinary shares were acquired. |
| 06/08/2026 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
Teva Pharmaceutical Industries, SEC Form 4, Insider Trading, Share Acquisition, Restricted Share Units, Director Transactions, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.